Physician Assistant Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Robert Ross

Physician Assistant Goose Creek, SC Physician Assistant

NPI 1023723715 CMS profile 11489052

7 S Alliance Dr Ste 211B, Goose Creek, SC 29445

Open in the dashboard

General payments

$4,270

164 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Robert Ross of Goose Creek, SC is reported in the CMS Open Payments database as having received $4,270 across 164 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,427 50
2024 General $1,708 69
2023 General $1,136 45

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robert Ross
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Robert Ross were reported at $1,427. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Robert Ross Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $0 $132 $37–$438 $132
2022 $0 $155 $48–$522 $149
2023 $1,136 $167 $52–$557 $160
2024 $1,708 $178 $55–$600 $164
2025 $1,427 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. AstraZeneca Pharmaceuticals LP $842 22 payments
  2. Lilly USA, LLC $650 22 payments
  3. Novo Nordisk Inc $402 18 payments
  4. AbbVie, Inc. $390 21 payments
  5. Otsuka America Pharmaceutical, Inc. $273 11 payments
  6. Pfizer Inc. $187 10 payments
  7. Exact Sciences Corporation $152 8 payments
  8. Genzyme Corporation $150 1 payment
  9. Cagent Vascular LLC $144 1 payment
  10. Amgen Inc. $141 7 payments
  11. Other $939 43 payments

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $4,270 164 payments
Products named General payments · program years 2023–2025
  1. FARXIGA $642 17 payments
  2. MOUNJARO $453 17 payments
  3. Ozempic $343 14 payments
  4. REXULTI $233 9 payments
  5. RYBELSUS $225 13 payments
  6. VRAYLAR $221 11 payments
  7. AIRSUPRA $200 4 payments
  8. NURTEC ODT $166 9 payments
  9. BREZTRI $162 3 payments
  10. Cologuard Collection Kit $152 8 payments
  11. Other $2,238 102 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 71 drugs

Part D claims

2,329

Median for Physician Assistant: 241

Drug cost

$330,889

Median for Physician Assistant: $4,110

Branded share of claims

17%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 55 $95,402
Farxiga Dapagliflozin Propanediol Brand 61 $83,613
Eliquis Apixaban Brand 22 $28,754
Jardiance Empagliflozin Brand 17 $26,982
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 31 $26,670
Mounjaro Tirzepatide Brand 21 $24,155
Rybelsus Semaglutide Brand 12 $15,248
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 13 $9,533
Rosuvastatin Calcium Generic 152 $1,746
Atorvastatin Calcium Generic 176 $1,610

The 10 drugs with the highest cost, of 71 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 21 billing codes

Paid by Medicare

$44,430

Of which drugs: $763

Medicare patients

156

Average age 72

Services billed

1,004

75 women, 81 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 49%
Arthritis 46%
Chronic kidney disease 43%
Ischemic heart disease 24%
COPD 17%
Heart failure 15%
Osteoporosis 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Influenza vaccine, trivalent derived from cell cultures 90661 Office 22 22 $763

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FARXIGA
  • AstraZeneca Pharmaceuticals LP $351
$351 61 —
MOUNJARO
  • Lilly USA, LLC $171
$171 21 —
VRAYLAR
  • AbbVie, Inc. $155
$155 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $47
  • Lilly USA, LLC $33
$80 17 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $70
$70 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

164 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record